**Name of Journal:** *World Journal of* *Gastroenterology*

**ESPS Manuscript NO:** 26096

**Manuscript Type: REVIEW**

**Human bocavirus: Current knowledge and future challenges**

Guido M *et al*. Human bocavirus

Marcello Guido, Maria Rosaria Tumolo, Tiziano Verri, Alessandro Romano, Francesca Serio, Mattia De Giorgi, Antonella De Donno, Francesco Bagordo, Antonella Zizza

**Marcello Guido,** **Francesca Serio,** **Mattia De Giorgi,** **Antonella De Donno, Francesco Bagordo,** Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy

**Maria Rosaria Tumolo,** **Antonella Zizza,** Institute of Clinical Physiology, National Research Council, 73100 Lecce, Italy

**Tiziano Verri,** Laboratory of Physiology, Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy

**Alessandro Romano,** Neuropathology Unit, Institute of Experimental Neurology and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

**Author contributions:** Guido M and Tumolo MR are co-first authors and equally contributed to this article; all authors contributed to the conception and design of the study, literature review and analysis, drafting, critical revision and editing of the manuscript, and approval of the final version to be published.

**Conflict-of-interest statement:** The authors declare no conflicts of interests for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** **Marcello Guido,** **Professor,** Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, Faculty of Sciences, University of Salento, Via Provinciale Lecce-Monteroni, 73100 Lecce, Italy. marcello.guido@unisalento.it

**Telephone:** +39-832-298686

**Fax:** +39-832-298626

**Received:** March 28, 2016

**Peer-review started:** April 1, 2016

**First decision:** May 12, 2016

**Revised:** August 30, 2016

**Accepted:** September 14, 2016

**Article in press:**

**Published online:**

**Abstract**

Human bocavirus (HBoV) is a parvovirus isolated about a decade ago and found worldwide in both respiratory samples, mainly from early life and children of 6-24 mo of age with acute respiratory infection, and in stool samples, from patients with gastroenteritis. Since then, other viruses related to the first HBoV isolate (HBoV1), namely HBoV2, HBoV3 and HBoV4, have been detected principally in human faeces. HBoVs are small non-enveloped single-stranded DNA viruses of ~5300 nucleotides, consisting of three open reading frames encoding the first two the non-structural protein 1 (NS1) and nuclear phosphoprotein (NP1) and the third the viral capsid proteins 1 and 2 (VP1 and VP2). HBoV pathogenicity remains to be fully clarified mainly due to the lack of animal models for the difficulties in replicating the virus in *in vitro* cell cultures, and the fact that HBoV infection is frequently accompanied by at least another viral and/or bacterial respiratory and/or gastroenteric pathogen infection. Current diagnostic methods to support HBoV detection include polymerase chain reaction, real-time PCR, enzyme-linked immunosorbent assay and enzyme immunoassay using recombinant VP2 or virus-like particle capsid proteins, although sequence-independent amplification techniques combined with next-generation sequencing platforms promise rapid and simultaneous detection of the pathogens in the future. This review presents the current knowledge on HBoV genotypes with emphasis on taxonomy, phylogenetic relationship and genomic analysis, biology, epidemiology, pathogenesis and diagnostic methods. The emerging discussion on HBoVs as true pathogen or innocent bystander is also emphasized.

**Key words:** Human bocavirus; Respiratory virus; Gastrointestinal virus; Pathogenesis; Epidemiology; Molecular tests; Immunoassay methods

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Four genotypes compose the genus *Bocavirus*: Human bocavirus (HBoV) 1, predominantly found in the respiratory tract; and, HBoV2, 3 and 4, mainly detected in stool and associated with gastroenteritis. Despite worldwide occurrence, human bocavirus infection remains poorly understood, and the comprehension of many aspects of these viruses’ biology (*i.e.,* taxonomy, phylogenetic relationships with other viruses, epidemiology, molecular mechanisms of interaction with human cells, association with other pathogens, *etc.*) is necessary to clarify whether they are harmless passengers or true pathogens. Development of new diagnostic tools for detection of human bocaviruses will support this type of research.

Guido M, Tumolo MR, Verri T, Romano A, Serio F, De Giorgi M, De Donno A, Bagordo F, Zizza A. Human bocavirus: Current knowledge and future challenges. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Human bocavirus (HBoV) is a parvovirus that was first identified in 2005 using a protocol based on DNase treatment, random PCR amplification, high-throughput sequencing and bioinformatics analysis. When this virus-screening technique was initially applied to nasopharyngeal swabs and washings from children with unresolved respiratory tract infections, it gave a positive result rate of 3.1%; hence, it was proposed that HBoV is a causative pathogen of respiratory tract diseases[1].

Three additional HBoV subtypes were subsequently identified in human stool samples, named as HBoV2, HBoV3 and HBoV4 to differentiate them from the first isolated subtype, named HBoV1[2-4]. Notably, studies of both respiratory and faecal samples have shown the presence of HBoV in association with other potential pathogens[5-8], which led to the hypothesis that the virus may be a harmless passenger rather than a true pathogen[9,10]. Moreover, the virus has been detected in other biological samples, including blood[11], saliva[12], faeces[13] and urine[14], as well as environmental samples, including river water[15] and sewage[16]. Conversely, recent research has raised concerns over its presence in transfusion medicine[17].

HBoV has been found in individuals of all ages, although it mainly affects infants aged 6-24 mo with respiratory symptoms[1,18,19]. Based upon Koch’s modified postulates, however, the virus cannot yet be confirmed as a causative agent of disease due to the lack of animal models and/or for the difficulties in replicating it in *in vitro* cultured cells[20-23]. Thus, research and discussion about the potential role of this pathogen (alone or in combination with other types of viruses) in patients with respiratory infections and gastroenteritis is on going.

In this review, we examine the current knowledge and recent findings on the taxonomy, biology, epidemiology, pathogenesis and diagnosis methods of HBoV.

**CLASSIFICATION AND BIOLOGY**

HBoV genotypes belong to the family *Parvoviridae*, subfamily *Parvovirinae*, genus *Bocavirus*,causing infection in vertebrates exclusively[1,18,24]. The family *Parvoviridae* also comprises the subfamily *Densovirinae*, which infects arthropods and shares no sequence homology with the other subfamily. The current classification of the International Committee on Taxonomy of Viruses database recognizes eight genera of the subfamily *Parvovirinae*: *Amdoparvovirus*, *Aveparvovirus*, *Bocaparvovirus*, *Copiparvovirus*, *Dependoparvovirus*, *Erythroparvovirus*, *Protoparvovirus* and *Tetraparvovirus*[24].

The name *Bocavirus* derives from the combination of the terms bovine parvovirus (BPV) and canine minute virus (CMV), and was based on the sequence similarities and genomic organization of these two close relatives[1,25]. The parvoviruses associated with human infections are parvovirus B19 (B19V), within the genus *Erythroparvovirus*, the apathogenic adeno-associated virus (AAV), belonging to the genus *Dependoparvovirus,* andthe recently discovered parvoviruses 4 (PARV4) and 5 (PARV5), affiliated with the new genus *Tetraparvovirus*[24]. The latter has not yet been associated with any clinical significances; based on similarity, however, it has been allocated to the new genus *Hokovirus*[26,27].

 Among the human parvoviruses, B19V is particularly relevant since it is acknowledged as the etiologic agent of erythema infectiosum (also known as fifth disease) and has been characterized as a causative agent of other conditions in both children (*e.g.,* transient arthritis) and adults (*e.g.,* non-immune hydrops fetalis, several auto-immune diseases, spontaneous abortion and arthropathies)[28-30]. Despite the close phylogenetic relationship between B19V and HBoV, they appear to be strongly divergent in nature. For example, B19V shows tropism for bone marrow and a lifelong persistence in heart tissue[31,32], while HBoV persists in lymphatic tissue and in tissues afflicted with chronic sinusitis[33,34].

Parvoviruses are small, icosahedral, non-enveloped viruses of 18-26 nm in diameter that contain a single molecule of linear, negative- or positive-sense, single-stranded DNA[1,35]. The length of the linear single-stranded HBoV genome is only ~5 kb, plus the terminal sequences of 32-52 nucleotides (nt) that play a key role in virus replication[36,37] and show high similarity to the terminal sequences of BPV and CMV[38].

The replication mechanism of HBoV has remained elusive, with two conflicting models proposed: rolling hairpin[23,32]versus rolling-cycle[39]. Replication of the other parvovirus occurs *via* the rolling-hairpin model, with generation of concatenameric intermediates characterized by a head-to-head or tail-to-tail structure. However, while the presence of head-to-head monomers has been demonstrated in HBoV1, HBoV2 and HBoV3, concatenameric intermediates have not been found yet[23,36,37,40,41].

Conversely, recent data support the hypothesis that HBoV, during its natural infection, can become persistently established in host cells by forming extra-chromosomal closed circular episomes, instead of concatemers[37,41]. To date, the episomal structure has been found for all the HBoV genotypes[36,37,40,41]. In addition, head-to-tail sequences of HBoV1 have been detected in samples from patients with respiratory infections[36]. Kapoor *et al*[37] identified the head-to-tail monomer in an episomal circular form (HBoV3-E1) of the HBoV3 genome from an intestinal biopsy of a child with gastrointestinal disease; the complete HBoV3-E1 genome was shown to contain 5319 nt, flanked with a 513 nt-long terminal non-coding sequence. Meanwhile, the HBoV2-C2 circular genome (5307 nt, of which 520 nt represent the non-coding terminal region) has been detected as well[41]. A recent study demonstrated that the replicative form of the HBoV4 genotype comprises a head-to-tail nucleotide sequence in circular form[40]. Future research efforts delving deeper into the HBoV replication mechanism are likely to improve our comprehension of the pathogenetic role of HBoV substantially[37] .

The genome of HBoV is organized in three open reading frames (ORFs): ORF1, encoding two forms of the non-structural (NS) protein NS1; ORF2, encoding an additional NS protein, the nuclear phosphoprotein NP1[38,42]; and, ORF3, encoding the two structural viral capsid proteins VP1 and VP2, which are generated as a result of alternative splicing events[1]. The non-coding regions contain palindromic sequences, commonly known as inverted terminal repeats, that are essential for viral replication[37,43]. NS1 is a multifunctional protein that has various sites with differing functions in the N-terminus (binding and endonuclease), C-terminus (transactivation) and middle region (ATPase and helicase)[44,45]. Furthermore, NS1 has a role in DNA replication, and, similar to NP1, its function is essential for DNA replication of CMV and minute virus of mice[46]. This non-structural protein also participates in apoptosis, cell-cycle arrest and gene transactivation in B19V[47,48].

Recently, novel small NS proteins (NS2, NS3 and NS4) have been identified in HBoV1 through studies based upon transfection of an HBoV1 infectious pro-viral plasmid and viral infection of polarized human airway epithelium cells cultured at an air-liquid interface (HAE-ALI). These proteins contain the predictive domains of NS1 activities; moreover, their function is important for viral DNA replication in the human embryonic kidney 293 (HEK293) cell line. NS2 plays a critical role in HBoV1 replication in HAE-ALI cultures as well[49]. NP1 is also a small non-structural protein, but for which the function(s) still need to be fully elucidated. Initially, NP1 from HBoV1 was shown to induce cell cycle arrest and apoptosis after transfection in HeLa cells[50]. Recent studies, however, have shown that HBoV1 NP1 plays a critical role in the expression of viral capsid proteins[51] and demonstrated its direct involvement in viral DNA replication at the replication origin (OriR)[52].

VP1 and VP2 share a C-terminal region and differ only in the N-terminal region of VP1 (VP1u)[53]. VP1u exerts phospholipase A2 activity, which is essential for infectivity and is facilitated by release of the virus from endocytic compartments to the nucleus of the host cell[42]. To date, the mechanism underlying the viral cell entry and *in vivo* host-range remains unclear[36].

The complete NS1 gene sequence of HBoV1 (NC\_007455.1) is 1928 nt long and encodes a polypeptide of 643 amino acid (aa) residues, much shorter than the NS1 of CMV and of BPV[46,54]. The HBoV1 NP1 gene is 660 nt long and its encoded protein varies in length among the different strains, ranging from 214 to 219 aa residues. Moreover, the HBoV1 VP1/VP2 ORF contains the complete coding sequence of the VP1 gene (3071 nt), encoding for a protein of 671 aa residues[4], and the VP2 gene within the VP1 sequence, encoded from nucleotide 3443 to 5071. The genomic organization of the different HBoV genotypes obtained using the Illustrator of Biological Sequences software package[55] is shown in Figure 1, and the phylogenetic trees of RefSeq nucleotide and aa coding regions of the HBoV genomes, as constructed by the Neighbor-Joining method implemented in the program MEGA5, are shown in Figure 2[56-58]. Remarkably, HBoV3 NS1 and NP1 sequences cluster with the homologous sequences of the HBoV1 strain, and the same holds true for HBoV2 and HBoV4. Conversely, the VP1/VP2 sequences of HBoV3 are similar to HBoV2, providing evidence that HBoV3 may have resulted from recombination between the HBoV1 and HBoV2 viruses (Figure 2)[3,4].

A low level of polymorphisms warrants a predominant role for recombination in a genome prone to rapid evolution[59], in a context in which both recombination and mutation represent major mechanisms of genetic variation in parvovirus evolution[60]. Thus, it is not surprising that it has been proposed recently for the human bocaviruses group to be rearranged into two clusters (or species): human bocaparvovirus 1 (including the previous HBoV1 and HBoV3) and human bocaparvovirus 2 (including the previous HBoV2 and HBoV4)[25].

**PATHOGENESIS**

As already stated, the pathogenesis of HBoV remains poorly characterized, mainly due to the lack of specific cell lines for virus culture or experimental animal models[18]. The first study presenting an *in vitro* culture system for HBoV dates back to 2009, wherein pseudostratified HAE-ALI, derived from primary human bronchial epithelial cells, was utilized as a tool for HBoV replication[22]. Attempts had been made previously with other cell lines (HEp-2, Vero, MRC-5, *etc*.) but were unsuccessful, most likely due to the lack of expression of certain receptor(s)[22,61,62], making these cells not susceptible to some respiratory viruses.

The HAE-ALI model was previously used to infect a wide range of respiratory RNA viruses, such as influenza viruses and human coronaviruses, among others, from the apical surface[63,64], unlike the respiratory DNA viruses, which were accomplished only from the basolateral surface[65]. The HBoV1 virions are capable of, both productively and persistently, infecting HAE from both the apical and basolateral surfaces; but, a consequence of this infection can be induction of airway epithelial damage, evidenced by loss of cilia, disruption of the tight junction barrier and epithelial cell hypertrophy[23,66]. Subsequently, commercially available HAE culture systems, namely EpiAirway (MatTek, Ashland, MA, United States) and MucilAir HAE (Epithelix Sàrl, Geneva, Switzerland), were tested for HBoV1 infection. Despite the same results as obtained by the HAE made in-house, an innovative finding was that HBoV1 infection was demonstrated to persist for as long as 50 d[67]. More recent data have displayed, for the first time, that HBoV1 infection of HAE-ALI induces a DNA damage response that facilitates viral genome amplification[68]. In parallel, other cell lines can be infected by HBoV; for example, it has been established that transfection of a HBoV1 infectious clone into HEK293 cells can generate high titre progeny virions[42,52].

The virus enters the host *via* the respiratory tract and through the bloodstream or by direct ingestion, reaching the gastrointestinal tract[69]. HBoV1 has been detected in both respiratory and gastrointestinal tract. Several studies have shown the association between HBoV1 and the upper and lower respiratory tract. In this regard, the most frequently described clinical presentation of HBoV1 infection includes cough, fever, rhinorrhea, asthma exacerbation, bronchiolitis, acute wheezing and pneumonia[1,5,18,19,70,71]. HBoV1 DNA has also been found in stool samples of adult patients with the gastrointestinal manifestations of nausea, vomiting and diarrhoea[72]. However, the HBoV1-load in stool samples of paediatric patients with acute gastroenteritis was reported to be lower than the viral loads in respiratory tract samples[73]. In fact, a viral load median of 1.88 x 104 genome/mL has been reported for stool samples, which is lower than that found in the nasopharyngeal aspirates (NPA) of patients with respiratory infections (4.9 × 103 copies/mL)[74,75]. HBoV2, as well as the other genotypes, is found more often in stool samples[18,40,76,77] and HBoV2, and possibly HBoV3, associates with gastroenteritis[3,10,78]. Among these, HBoV2 has been the only species isolated from NPA of children hospitalized with acute respiratory tract infections[79]. More recent data show that HBoV can be detected directly and specifically in tissues such as the duodenum, paranasal sinus mucosa and intestinal biopsies[34,37,39].

HBoV mono-infections are rare, while double-infections are observed frequently[9,80]. Cases of HBoV infection show a high rate of co-infections with other viral and bacterial respiratory and gastroenteritis pathogens, such as human rhinovirus, adenovirus, norovirus, rotavirus[6,73,81-83]. Notably, co-infecting pathogens have been found in up to 83% of respiratory samples[14,18,70,84]. In particular, co-infection with respiratory syncytial virus (RSV) occurs very frequently (89.5%)[85]. HBoV1 remains detectable in NPA samples of immune-competent subjects for up to 6 months after infection[86,87]. Consequently, HBoV1 is often detectable with other viruses in asymptomatic patients, facilitating the reactivation of a latent virus by a super-infection[88]. Despite a low tropism of the virus being demonstrated in the human body[31,89], HBoV shows a high persistence in some sites, in particular the lymphatic tissue[33]. The persistence and reactivation of HBoV may explain the high prevalence of co-infections[90], although its effects and mechanisms are still unclear and its contribution to active disease remains to be accurately established[88]. In addition, individuals with low viral load are more likely to be co-infected with other pathogens compared to those with high viral load (57% *vs* 38.9%)[84]. Clinically relevant infections, requiring hospitalization of the subject, are associated with co-infections of up to six different pathogens in a single patient[91,92]. Furthermore, high viral load (> 104 copies/mL) has been shown in multiple studies to be statistically associated with severe clinical manifestations and longer hospitalization[35,84,93]. In contrast to these findings, however, Ghietto *et al*[85], who screened 1135 respiratory samples from children and adults, both symptomatic and asymptomatic, found no association between high viral load and illness; yet, they did demonstrate that all asymptomatic subjects had a low viral load (*P* < 0.005). High viral load (> 106 copies/mL) in NPA was reported by Christensen *et al*[94]; their study also demonstrated that viremia was more frequent in the subjects with high viral load (70%) than in those with a moderate or low virus load (10%). Hence, on the basis of the data reported in the literature to date, the role of this virus as a harmless passenger, rather than a true infecting agent, is still debatable, and, therefore, it remains to be established.

In the host, T-helper (Th) cells are essential for antiviral immunity since they participate in the antiviral responses both directly and indirectly. Their direct activities are exerted *via* their production of antiviral cytokines, whereas their indirect activities are mediated *via* the Th patterns that promote B cells and cytotoxic T cells[95]. In a study of NPA from children with acute bronchiolitis, Chung *et al*[96] demonstrated higher concentrations of interferon-gamma (IFN-γ), interleukin (IL)-2 and IL-4 in the HBoV-positive subjects, compared to the asymptomatic controls; however, the cytokine levels of IL-10 and tumour necrosis factor-alpha were lower than those found in RSV-positive children. Furthermore, other studies demonstrated that HBoV1 induces IFN-γ against HBoV VP2 VLPs, IL-10 and IL-13 (Th2 cells) in CD4+ T cells[97,98]. These findings suggest that HBoV infection can induce production of Th1 and Th2 cytokines. To date, however, the precise mechanisms underlying HBoV-specific T cell immunity have not been defined.

**EPIDEMIOLOGY**

HBoV has a worldwide distribution; its transmission and infection occurs throughout the year but is predominant during winter and spring months[19,98]. The worldwide distribution of HBoV involves infections of the respiratory tract and gastrointestinal tract (as evidenced in stool samples) of children as well as adults in Europe[2,83], Asia[6,76,77], the Americas[37,74, 78,82], Africa[4] and Australia[3].

We estimated the global prevalence of infection based upon a search of articles published in the Medline database from September 6, 2005 (the year of HBoV discovery) to March 15, 2016 and including studies evaluating respiratory and gastrointestinal HBoV infection (Tables 1 and 2 respectively). For each country, we calculated prevalence estimates, 95% confidence intervals (CIs) and per cent of co-infections based on pooled data from all eligible studies and extracted data in a customised database. In total, we used 357 reports on the prevalence of HBoV correlated to respiratory illness and to gastrointestinal infections (Appendix A).

The average prevalence of HBoV in respiratory tract samples ranged from 1.0% (CI: 0.0-2.0) to 56.8% (CI: 46.9-66.8) (Table 1) and in stool specimens from 1.3% (CI: 0.0-3.9) to 63% (CI: 55.0-71.1), depending on the country (Table 2).Furthermore, the worldwide HBoV total prevalence estimates in respiratory infections is 6.3% (CI: 6.2-6.4) and in gastrointestinal infections is 5.9% (CI: 5.7-6.1) (Table 1 and Table 2). With respect to the respiratory tract infections, prevalence averages < 2% have been reported for Cambodia (1.6%, CI: 1.2-2.0), Kenya (1.8%, CI: 0.5-3.2), Kuwait (1.9%, CI: 0.9-2.9), Senegal (1.0%, CI: 0.0-2.0) and the Philippines (1.0%, CI: 0.5-1.6). In contrast, the highest prevalence averages have been reported for Egypt (56.8%, CI: 46.9-66.8), Hungary (29.8%, CI: 20.5-39.0) and Nicaragua (33.3%, CI: 26.7-40.0) (Table 1).

Based on data available for gastrointestinal infections, countries such as Mexico and Russia have mostly low endemicity levels (1.3%, CI: 0.0-3.9 and 1.4%, CI: 1.1-1.6 respectively); conversely, high HBoV prevalence has been reported for Bangladesh (63.0%, CI: 55.0-77.1), Nigeria (29.2%, CI: 20.1-38.3) and Tunisia (58.3%, CI: 48.5-68.2) (Table 2).

The rate of co-infections in subjects with respiratory infections and HBoV-positivity ranges from 8.3% (CI: 0.0-19.4) to 100% (Table 1); meanwhile, the co-infection ratio is 46.7% (CI: 44.2-49.2) relative to the gastrointestinal manifestations (Table 2).

The seroprevalence of HBoV is age-related and ranges from ~40% in children between 18 and 23 mo of age up to virtually 100% in children older than 2 years, with an average of 76.6% in children and 96% in adults[99,100]. A serological survey performed in Italy and involving 1206 participants was carried out with the aim of determining the presence of anti-HBoV IgG antibodies; the study showed a higher seropositive rate in children of 5-9 years of age (96.4%), with respect to those of 2-4 years of age (64.2%). Furthermore, the high seroprevalence observed in infants aged 0–5 mo (73.7%) and in children during the first months of life (51.4%) is assumed to be related to maternal antibodies[101]. Kantola *et al*[99] showed that the HBoVs infecting humans most frequently were, in descending order, HBoV1, HBoV2, HBoV3 and HBoV4. A recent seroprevalence study conducted in Beijing and Nanjing and involving 1391 samples showed the prevalence of HBoV1 and HBoV2 to be 73.4% (1021) and 70.5% (981) respectively[102]; the results for HBoV1 were consistent with previous serological research conducted in Japan (71.1%)[100] and Jamaica (76.7%)[103]. These findings indicate a high degree of antigenic cross-reactivity between HBoV1 and HBoV2[102].

Conversely, the discrepancy observed in HBoV2 seroprevalence (70.5% *vs* 20.4%)[104] is most likely due to differences in the methods used; in fact, while enzyme-linked immunosorbent assay (ELISA) indicate the exposure rate of accumulated infections, PCR results only reveal an on-going infection[102].

**DIAGNOSTICS**

For many years, the diagnostic tools available for identification of the etiological agents associated with respiratory and gastroenteric diseases have been limited. At first, the main method to detect HBoV infections in respiratory and gastrointestinal samples was represented by a direct tool, namely conventional PCR[5-7,13,19,61,62,72,80,105-114], which was followed by nested and real-time (RT)-PCR[8,10,11,33,35,61,67,70,73,81,112,115-117].

PCR techniques enable isolation of viral genome fragments from NPA, broncho-alveolar, stool, serum and urine specimens through amplification of NP1, NS1 or/and the VP1/2 gene regions[9], or *via* other nucleic acid-based detection HBoV diagnosis methods[118-120]. NP1 and NS1 are more conserved than VP1/2, and thus are commonly targeted for PCR-based detection of the virus[13,111,121]. RT-PCR has an advantage over conventional PCR, being more specific and rapid, but its requirement for higher-cost oligoprobes is limiting[11].

Application of RT-PCR to NP1 and VP1 genes for the detection of HBoV in swabs, faecal and whole blood samples allowed Tozer *et al*[11] to achieve clinical sensitivity of 100% and clinical specificity of 94% and 93% respectively for the NP1 and VP1 assays. Subsequently, multiplexing assays were developed to detect HBoV genotypes in respiratory infections; these included the commercially available Luminex RVP (Luminex Molecular Diagnostics, Toronto, Canada) and RespiFinder (Pathofinder, Maastricht, the Netherlands)[69,122,123]. More recently, sequence-independent amplification techniques combined with next-generation sequencing platforms have been introduced, promising rapid and simultaneous detection of numerous pathogens. Despite their current drawbacks (*i.e.,* high cost, labour intensity, long turnaround time, specific training of personnel, *etc.*), as opposed to RT-PCR, these new approaches can provide more information regarding virus species/type; hence, they are of interest for virus diagnosis in clinical and public health settings[124].

Serological methods have been developed for the estimation of HBoV-specific antibodies in serum samples; western blotting and immunofluorescence are among those[104,125]. ELISA and enzyme immunoassay (EIA) are reliable qualitative and quantitative serologic assays used to detect IgG and IgM antibodies and IgG affinity[99] using recombinant VP2 or VLP capsid proteins[126]; the latter, for example, is produced by an insect cell line infected with a baculovirus vector and subsequently used to produce rabbit anti-HBoV antisera that is applied to develop an ELISA test[127,128]. The IgG avidity test allows distinguishment between primary and secondary infections or immune-activations with high diagnostic specificity[129]. Recent data have indicated that children with pre-existing HBoV2 immunity show cross-reactivity with HBoV1, which presents a paradigm of the hypothesized Original Antigenic Sin phenomenon[130]. The few available serological studies to date have mainly addressed epidemiologic issues[97,101,103,125,127,131]; however, considering that human bocaviruses are highly prevalent agents that can establish persistent infections, interpretation of the serological tests in the context of the clinical situation may be just as complicated as using the PCR results[126].

Notably, Zaghloul[132] determined the presence of HBoV in children *via* qualitative PCR detection of NPA and ELISA estimation of IgM antibodies in serum. Both assays were highly sensitive and specific; however, the ELISA had lower sensitivity than the PCR (81.8% *vs* 100%) but higher specificity (100% *vs* 78%).

**CONCLUSION AND FUTURE CHALLENGE**

Based on the current data, the pathogenic roles of the various HBoV genotypes in respiratory tract illness and gastrointestinal infections remain unresolved. It is possible that the virus may be both a passenger and a causative pathogen of acute respiratory tract and gastrointestinal diseases. The conflicting ideas on this pathogenic role mainly come from the fact that the Koch’s revised postulates cannot be applied to HBoV, because neither an effective method for virus culture nor an animal model of infection is available in practice to date. Moreover, several studies have indicated that HBoV requires the presence of other agents to carry out the infection.

Recent studies have demonstrated that HBoV1 infection of HAE-ALI induces a DNA damage response that facilitates viral genome amplification[68]. Nonetheless, further research to develop cell lines and animal models suitable for viral replication is needed in order to obtain more evidence to better understand the natural course of HBoV infection. In this respect, simpler culturing methods and infectious clones should be made available, since HBoV genomic analysis is difficult just for this reason[38].

In spite of a relatively substantial amount of knowledge on the molecular basis of the HBoV life cycle, the function of several HBoV proteins still requires further investigation. For instance, only recently were three novel small NS proteins (NS2, NS3 and NS4) identified; among these, only one NS protein is critical to the replication of the virus in polarized human bronchial airway epithelium[49]. The role of the other proteins remains rather uncertain.

Most of the studies to date have been performed on the HBoV1 genotype, whereas little information is available about the other agents. Notably, the presence of HBoV2, HBoV3 and HBoV4 in the respiratory tract should be further investigated, as well as their phylogenetic relationships. Our phylogenetic analysis suggests, as shown by other authors[3,4], that HBoV3 may result from the recombination of HBoV1 and HBoV2; but, it may also be a hybrid of HBoV1, with a common ancestor of HBoV2 and HBoV4[133]. In this respect, it would be appropriate for the future studies to test more, and simultaneously, (possibly all) genotypes and genes.

HBoV subtypes have been found worldwide, without any regional, geographic or border restrictions. HBoV1 is associated with paediatric respiratory illness but also with gastrointestinal symptoms[6,134]. HBoV2, HBoV3 and HBoV4 are more frequently detected in stool samples and seem to be enteric[4,107,135]. Moreover, the most typical age for HBoV infection is < 2-years-old; only rarely has it been found in adults and the elderly[12]. In this respect, clinical studies would be useful to characterize disease pathogenesis and to understand immunity in the various populations represented by infants, the elderly or immunocompromised individuals responding to HBoV infection.

There is also a need to optimize commercial diagnostic reagents and methods for HBoV identification. Overall, HBoV detection is mainly performed *via* molecular techniques (*i.e.,* PCR and RT-PCR)[10]; only rarely is it done with serological methods (*i.e.,* ELISA, EIA, Western blotting and immunofluorescence), due to the lack of commercial kits[99,103,125,126]. Furthermore, developing new sequence-independent amplification techniques combined with next generation sequencing platforms is worthy to achieve rapid and simultaneous detection of numerous pathogens[124].

Finally, were the pathogenic role of HBoV to be confirmed, the development of an effective vaccine to control the spread of infection should be of primary importance. With the hope of achieving this goal, many studies have been performed on the HBoV viral capsid proteins. Previous research studies have confirmed that VLPs can be used as safe and effective vaccines. Recently, *in vitro* studies have demonstrated that HBoV VP2 VLPs have good immunogenicity and studies in mice have shown they can induce strong humoral and cellular immune responses, indicating their promise as candidate proteins for HBoV vaccine[136]. Newer data suggest that the creation of non-replicating infectious HBoV1 mutants may represent a new approach for HBoV vaccine development[49].

In conclusion, a better understanding of the natural course of HBoV infection, the implementation of experimental systems to analyse the replication cycle in more detail and the development of specific therapies are important and urgent needs.

**REFERENCES**

1 **Allander T**, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. *Proc Natl Acad Sci U S A* 2005; **102**: 12891-12896 [PMID: 16118271 DOI: 10.1073/pnas.0504666102]

2 **Kapoor A**, Slikas E, Simmonds P, Chieochansin T, Naeem A, Shaukat S, Alam MM, Sharif S, Angez M, Zaidi S, Delwart E. A newly identified bocavirus species in human stool. *J Infect Dis* 2009; **199**: 196-200 [PMID: 19072716 DOI: 10.1086/595831]

3 **Arthur JL**, Higgins GD, Davidson GP, Givney RC, Ratcliff RM. A novel bocavirus associated with acute gastroenteritis in Australian children. *PLoS Pathog* 2009; **5**: e1000391 [PMID: 19381259 DOI: 10.1371/journal.ppat.1000391]

4 **Kapoor A**, Simmonds P, Slikas E, Li L, Bodhidatta L, Sethabutr O, Triki H, Bahri O, Oderinde BS, Baba MM, Bukbuk DN, Besser J, Bartkus J, Delwart E. Human bocaviruses are highly diverse, dispersed, recombination prone, and prevalent in enteric infections. *J Infect Dis* 2010; **201**: 1633-1643 [PMID: 20415538 DOI: 10.1086/652416]

5 **Bastien N**, Brandt K, Dust K, Ward D, Li Y. Human Bocavirus infection, Canada. *Emerg Infect Dis* 2006; **12**: 848-850 [PMID: 16704852 DOI: 10.3201/eid1205.051424]

6 **Lau SK**, Yip CC, Que TL, Lee RA, Au-Yeung RK, Zhou B, So LY, Lau YL, Chan KH, Woo PC, Yuen KY. Clinical and molecular epidemiology of human bocavirus in respiratory and fecal samples from children in Hong Kong. *J Infect Dis* 2007; **196**: 986-993 [PMID: 17763318 DOI: 10.1086/521310]

7 **Christensen A**, Nordbø SA, Krokstad S, Rognlien AG, Døllner H. Human bocavirus commonly involved in multiple viral airway infections. *J Clin Virol* 2008; **41**: 34-37 [PMID: 18069054 DOI: 10.1016/j.jcv.2007.10.025]

8 **Esposito S**, Bosis S, Niesters HG, Tremolati E, Sabatini C, Porta A, Fossali E, Osterhaus AD, Principi N. Impact of human bocavirus on children and their families. *J Clin Microbiol* 2008; **46**: 1337-1342 [PMID: 18287315 DOI: 10.1128/JCM.02160-07]

9 **Schildgen O**, Müller A, Allander T, Mackay IM, Völz S, Kupfer B, Simon A. Human bocavirus: passenger or pathogen in acute respiratory tract infections? *Clin Microbiol Rev* 2008; **21**: 291-304, table of contents [PMID: 18400798 DOI: 10.1128/CMR.00030-07]

10 **Chow BD**, Esper FP. The human bocaviruses: a review and discussion of their role in infection. *Clin Lab Med* 2009; **29**: 695-713 [PMID: 19892229 DOI: 10.1016/j.cll.2009.07.010]

11 **Tozer SJ**, Lambert SB, Whiley DM, Bialasiewicz S, Lyon MJ, Nissen MD, Sloots TP. Detection of human bocavirus in respiratory, fecal, and blood samples by real-time PCR. *J Med Virol* 2009; **81**: 488-493 [PMID: 19152414 DOI: 10.1002/jmv.21409]

12 **Martin ET**, Taylor J, Kuypers J, Magaret A, Wald A, Zerr D, Englund JA. Detection of bocavirus in saliva of children with and without respiratory illness. *J Clin Microbiol* 2009; **47**: 4131-4132 [PMID: 19794045 DOI: 10.1128/JCM.01508-09]

13 **Lee JI**, Chung JY, Han TH, Song MO, Hwang ES. Detection of human bocavirus in children hospitalized because of acute gastroenteritis. *J Infect Dis* 2007; **196**: 994-997 [PMID: 17763319 DOI: 10.1086/521366]

14 **Wang K**, Wang W, Yan H, Ren P, Zhang J, Shen J, Deubel V. Correlation between bocavirus infection and humoral response, and co-infection with other respiratory viruses in children with acute respiratory infection. *J Clin Virol* 2010; **47**: 148-155 [PMID: 20022295 DOI: 10.1016/j.jcv.2009.11.015]

15 **Hamza IA**, Jurzik L, Wilhelm M, Uberla K. Detection and quantification of human bocavirus in river water. *J Gen Virol* 2009; **90**: 2634-2637 [PMID: 19656966 DOI: 10.1099/vir.0.013557-0]

16 **Räsänen S**, Lappalainen S, Kaikkonen S, Hämäläinen M, Salminen M, Vesikari T. Mixed viral infections causing acute gastroenteritis in children in a waterborne outbreak. *Epidemiol Infect* 2010; **138**: 1227-1234 [PMID: 20092670 DOI: 10.1017/S0950268809991671]

17 **Li H**, He M, Zeng P, Gao Z, Bian G, Yang C, Li W. The genomic and seroprevalence of human bocavirus in healthy Chinese plasma donors and plasma derivatives. *Transfusion* 2015; **55**: 154-163 [PMID: 25052026 DOI: 10.1111/trf.12785]

18 **Jartti T**, Hedman K, Jartti L, Ruuskanen O, Allander T, Söderlund-Venermo M. Human bocavirus-the first 5 years. *Rev Med Virol* 2012; **22**: 46-64 [PMID: 22038931 DOI: 10.1002/rmv.720]

19 **Kesebir D**, Vazquez M, Weibel C, Shapiro ED, Ferguson D, Landry ML, Kahn JS. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. *J Infect Dis* 2006; **194**: 1276-1282 [PMID: 17041854 DOI: 10.1086/508213]

20 **Fredricks DN**, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. *Clin Microbiol Rev* 1996; **9**: 18-33 [PMID: 8665474]

21 **Ong DS**, Schuurman R, Heikens E. Human bocavirus in stool: A true pathogen or an innocent bystander? *J Clin Virol* 2016; **74**: 45-49 [PMID: 26655268 DOI: 10.1016/j.jcv.2015.11.027]

22 **Dijkman R**, Koekkoek SM, Molenkamp R, Schildgen O, van der Hoek L. Human bocavirus can be cultured in differentiated human airway epithelial cells. *J Virol* 2009; **83**: 7739-7748 [PMID: 19474096 DOI: 10.1128/JVI.00614-09]

23 **Huang Q**, Deng X, Yan Z, Cheng F, Luo Y, Shen W, Lei-Butters DC, Chen AY, Li Y, Tang L, Söderlund-Venermo M, Engelhardt JF, Qiu J. Establishment of a reverse genetics system for studying human bocavirus in human airway epithelia. *PLoS Pathog* 2012; **8**: e1002899 [PMID: 22956907 DOI: 10.1371/journal.ppat.1002899]

24 **Cotmore SF**, Agbandje-McKenna M, Chiorini JA, Mukha DV, Pintel DJ, Qiu J, Soderlund-Venermo M, Tattersall P, Tijssen P, Gatherer D, Davison AJ. The family Parvoviridae. *Arch Virol* 2014; **159**: 1239-1247 [PMID: 24212889 DOI: 10.1007/s00705-013-1914-1]

25 **Chen KC**, Shull BC, Moses EA, Lederman M, Stout ER, Bates RC. Complete nucleotide sequence and genome organization of bovine parvovirus. *J Virol* 1986; **60**: 1085-1097 [PMID: 3783814]

26 **Fryer JF**, Kapoor A, Minor PD, Delwart E, Baylis SA. Novel parvovirus and related variant in human plasma. *Emerg Infect Dis* 2006; **12**: 151-154 [PMID: 16494735 DOI: 10.3201/eid1201.050916]

27 **Lau SK**, Woo PC, Tse H, Fu CT, Au WK, Chen XC, Tsoi HW, Tsang TH, Chan JS, Tsang DN, Li KS, Tse CW, Ng TK, Tsang OT, Zheng BJ, Tam S, Chan KH, Zhou B, Yuen KY. Identification of novel porcine and bovine parvoviruses closely related to human parvovirus 4. *J Gen Virol* 2008; **89**: 1840-1848 [PMID: 18632954 DOI: 10.1099/vir.0.2008/000380-0]

28 **Heegaard ED**, Brown KE. Human parvovirus B19. *Clin Microbiol Rev* 2002; **15**: 485-505 [PMID: 12097253 DOI: 10.1128/CMR.15.3.485-505.2002]

29 **Riipinen A**, Väisänen E, Nuutila M, Sallmen M, Karikoski R, Lindbohm ML, Hedman K, Taskinen H, Söderlund-Venermo M. Parvovirus b19 infection in fetal deaths. *Clin Infect Dis* 2008; **47**: 1519-1525 [PMID: 18991512 DOI: 10.1086/593190]

30 **Colmegna I**, Alberts-Grill N. Parvovirus B19: its role in chronic arthritis. *Rheum Dis Clin North Am* 2009; **35**: 95-110 [PMID: 19480999 DOI: 10.1016/j.rdc.2009.03.004]

31 **Kuethe F**, Lindner J, Matschke K, Wenzel JJ, Norja P, Ploetze K, Schaal S, Kamvissi V, Bornstein SR, Schwanebeck U, Modrow S. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. *Clin Infect Dis* 2009; **49**: 1660-1666 [PMID: 19863443 DOI: 10.1086/648074]

32 **Schildgen V**, Lüsebrink J, Tillmann RL, Wulfert M, Gattermann N, Schildgen O. Human bocavirus is not detectable in bone marrow from patients with myelodysplastic syndromes. *Influenza Other Respir Viruses* 2011; **5**: 221-222 [PMID: 21651730 DOI: 10.1111/j.1750-2659.2011.00200.x]

33 **Lu X**, Gooding LR, Erdman DD. Human bocavirus in tonsillar lymphocytes. *Emerg Infect Dis* 2008; **14**: 1332-1334 [PMID: 18680679 DOI: 10.3201/eid1408.080300]

34 **Falcone V**, Ridder GJ, Panning M, Bierbaum S, Neumann-Haefelin D, Huzly D. Human bocavirus DNA in paranasal sinus mucosa. *Emerg Infect Dis* 2011; **17**: 1564-1565 [PMID: 21801654 DOI: 10.3201/eid1708.101944]

35 **Allander T**, Jartti T, Gupta S, Niesters HG, Lehtinen P, Osterback R, Vuorinen T, Waris M, Bjerkner A, Tiveljung-Lindell A, van den Hoogen BG, Hyypiä T, Ruuskanen O. Human bocavirus and acute wheezing in children. *Clin Infect Dis* 2007; **44**: 904-910 [PMID: 17342639 DOI: 10.1086/512196]

36 **Lüsebrink J**, Schildgen V, Tillmann RL, Wittleben F, Böhmer A, Müller A, Schildgen O. Detection of head-to-tail DNA sequences of human bocavirus in clinical samples. *PLoS One* 2011; **6**: e19457 [PMID: 21573237 DOI: 10.1371/journal.pone.0019457]

37 **Kapoor A**, Hornig M, Asokan A, Williams B, Henriquez JA, Lipkin WI. Bocavirus episome in infected human tissue contains non-identical termini. *PLoS One* 2011; **6**: e21362 [PMID: 21738642 DOI: 10.1371/journal.pone.0021362]

38 **Schildgen O**, Qiu J, Söderlund-Venermo M. Genomic features of the human bocaviruses. *Future Virol* 2012; **7**: 31-39 [PMID: 22389649 DOI: 10.2217/fvl.11.136]

39 **Streiter M**, Malecki M, Prokop A, Schildgen V, Lüsebrink J, Guggemos A, Wisskirchen M, Weiss M, Cremer R, Brockmann M, Schildgen O. Does human bocavirus infection depend on helper viruses? A challenging case report. *Virol J* 2011; **8**: 417 [PMID: 21871135 DOI: 10.1186/1743-422X-8-417]

40 **Babkin IV**, Tyumentsev AI, Tikunov AY, Zhirakovskaia EV, Netesov SV, Tikunova NV. A study of the human bocavirus replicative genome structures. *Virus Res* 2015; **195**: 196-202 [PMID: 25449911 DOI: 10.1016/j.virusres.2014.10.019]

41 **Zhao H**, Zhao L, Sun Y, Qian Y, Liu L, Jia L, Zhang Y, Dong H. Detection of a bocavirus circular genome in fecal specimens from children with acute diarrhea in Beijing, China. *PLoS One* 2012; **7**: e48980 [PMID: 23133667 DOI: 10.1371/journal.pone.0048980]

42 **Gurda BL**, Parent KN, Bladek H, Sinkovits RS, DiMattia MA, Rence C, Castro A, McKenna R, Olson N, Brown K, Baker TS, Agbandje-McKenna M. Human bocavirus capsid structure: insights into the structural repertoire of the parvoviridae. *J Virol* 2010; **84**: 5880-5889 [PMID: 20375175 DOI: 10.1128/JVI.02719-09]

43 **Chen AY**, Cheng F, Lou S, Luo Y, Liu Z, Delwart E, Pintel D, Qiu J. Characterization of the gene expression profile of human bocavirus. *Virology* 2010; **403**: 145-154 [PMID: 20457462 DOI: 10.1016/j.virol.2010.04.014]

44 **Tewary SK**, Zhao H, Shen W, Qiu J, Tang L. Structure of the NS1 protein N-terminal origin recognition/nickase domain from the emerging human bocavirus. *J Virol* 2013; **87**: 11487-11493 [PMID: 23966383 DOI: 10.1128/JVI.01770-13]

45 **Smith RH**, Spano AJ, Kotin RM. The Rep78 gene product of adeno-associated virus (AAV) self-associates to form a hexameric complex in the presence of AAV ori sequences. *J Virol* 1997; **71**: 4461-4471 [PMID: 9151837]

46 **Sun Y**, Chen AY, Cheng F, Guan W, Johnson FB, Qiu J. Molecular characterization of infectious clones of the minute virus of canines reveals unique features of bocaviruses. *J Virol* 2009; **83**: 3956-3967 [PMID: 19211770 DOI: 10.1128/JVI.02569-08]

47 **Hsu TC**, Wu WJ, Chen MC, Tsay GJ. Human parvovirus B19 non-structural protein (NS1) induces apoptosis through mitochondria cell death pathway in COS-7 cells. *Scand J Infect Dis* 2004; **36**: 570-577 [PMID: 15370668 DOI: 10.1080/00365540410016230]

48 **Hsu TC**, Tzang BS, Huang CN, Lee YJ, Liu GY, Chen MC, Tsay GJ. Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells. *Clin Exp Immunol* 2006; **144**: 152-157 [PMID: 16542377 DOI: 10.1111/j.1365-2249.2006.03023.x]

49 **Shen W**, Deng X, Zou W, Cheng F, Engelhardt JF, Yan Z, Qiu J. Identification and Functional Analysis of Novel Nonstructural Proteins of Human Bocavirus 1. *J Virol* 2015; **89**: 10097-10109 [PMID: 26223640 DOI: 10.1128/JVI.01374-15]

50 **Sun B**, Cai Y, Li Y, Li J, Liu K, Li Y, Yang Y. The nonstructural protein NP1 of human bocavirus 1 induces cell cycle arrest and apoptosis in Hela cells. *Virology* 2013; **440**: 75-83 [PMID: 23507451 DOI: 10.1016/j.virol.2013.02.013]

51 **Zou W**, Cheng F, Shen W, Engelhardt JF, Yan Z, Qiu J. Nonstructural Protein NP1 of Human Bocavirus 1 Plays a Critical Role in the Expression of Viral Capsid Proteins. *J Virol* 2016; **90**: 4658-4669 [PMID: 26912614 DOI: 10.1128/JVI.02964-15]

52 **Shen W**, Deng X, Zou W, Engelhardt JF, Yan Z, Qiu J. Analysis of cis and trans Requirements for DNA Replication at the Right-End Hairpin of the Human Bocavirus 1 Genome. *J Virol* 2016; **90**: 7761-7777 [PMID: 27334591 DOI: 10.1128/JVI.00708-16]

53 **Lindner J**, Modrow S. Human bocavirus--a novel parvovirus to infect humans. *Intervirology* 2008; **51**: 116-122 [PMID: 18536522 DOI: 10.1159/000137411]

54 **Qiu J**, Cheng F, Johnson FB, Pintel D. The transcription profile of the bocavirus bovine parvovirus is unlike those of previously characterized parvoviruses. *J Virol* 2007; **81**: 12080-12085 [PMID: 17715221 DOI: 10.1128/JVI.00815-07]

55 **Liu W**, Xie Y, Ma J, Luo X, Nie P, Zuo Z, Lahrmann U, Zhao Q, Zheng Y, Zhao Y, Xue Y, Ren J. IBS: an illustrator for the presentation and visualization of biological sequences. *Bioinformatics* 2015; **31**: 3359-3361 [PMID: 26069263 DOI: 10.1093/bioinformatics/btv362]

56 **Lole KS**, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. *J Virol* 1999; **73**: 152-160 [PMID: 9847317]

57 **Sievers F**, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol* 2011; **7**: 539 [PMID: 21988835 DOI: 10.1038/msb.2011.75]

58 **Tamura K**, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol* 2011; **28**: 2731-2739 [PMID: 21546353 DOI: 10.1093/molbev/msr121]

59 **Zehender G**, De Maddalena C, Canuti M, Zappa A, Amendola A, Lai A, Galli M, Tanzi E. Rapid molecular evolution of human bocavirus revealed by Bayesian coalescent inference. *Infect Genet Evol* 2010; **10**: 215-220 [PMID: 19932194 DOI: 10.1016/j.meegid.2009.11.011]

60 **Lau SK**, Woo PC, Yip CC, Li KS, Fu CT, Huang Y, Chan KH, Yuen KY. Co-existence of multiple strains of two novel porcine bocaviruses in the same pig, a previously undescribed phenomenon in members of the family Parvoviridae, and evidence for inter- and intra-host genetic diversity and recombination. *J Gen Virol* 2011; **92**: 2047-2059 [PMID: 21632566 DOI: 10.1099/vir.0.033688-0]

61 **Foulongne V**, Rodière M, Segondy M. Human Bocavirus in children. *Emerg Infect Dis* 2006; **12**: 862-863 [PMID: 16710957 DOI: 10.3201/eid1205.051523]

62 **Ma X**, Endo R, Ishiguro N, Ebihara T, Ishiko H, Ariga T, Kikuta H. Detection of human bocavirus in Japanese children with lower respiratory tract infections. *J Clin Microbiol* 2006; **44**: 1132-1134 [PMID: 16517912 DOI: 10.1128/JCM.44.3.1132-1134.2006]

63 **Ilyushina NA**, Ikizler MR, Kawaoka Y, Rudenko LG, Treanor JJ, Subbarao K, Wright PF. Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium. *J Virol* 2012; **86**: 11725-11734 [PMID: 22915797 DOI: 10.1128/JVI.01477-12]

64 **Pyrc K**, Sims AC, Dijkman R, Jebbink M, Long C, Deming D, Donaldson E, Vabret A, Baric R, van der Hoek L, Pickles R. Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures. *J Virol* 2010; **84**: 11255-11263 [PMID: 20719951 DOI: 10.1128/JVI.00947-10]

65 **Zabner J**, Freimuth P, Puga A, Fabrega A, Welsh MJ. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. *J Clin Invest* 1997; **100**: 1144-1149 [PMID: 9276731 DOI: 10.1172/JCI83931]

66 **Deng X**, Yan Z, Luo Y, Xu J, Cheng F, Li Y, Engelhardt JF, Qiu J. In vitro modeling of human bocavirus 1 infection of polarized primary human airway epithelia. *J Virol* 2013; **87**: 4097-4102 [PMID: 23345515 DOI: 10.1128/JVI.03132-12]

67 **Deng X**, Li Y, Qiu J. Human bocavirus 1 infects commercially available primary human airway epithelium cultures productively. *J Virol Methods* 2014; **195**: 112-119 [PMID: 24134939 DOI: 10.1016/j.jviromet.2013.10.012]

68 **Deng X**, Yan Z, Cheng F, Engelhardt JF, Qiu J. Replication of an Autonomous Human Parvovirus in Non-dividing Human Airway Epithelium Is Facilitated through the DNA Damage and Repair Pathways. *PLoS Pathog* 2016; **12**: e1005399 [PMID: 26765330 DOI: 10.1371/journal.ppat.1005399]

69 **Schildgen O**. Human bocavirus: lessons learned to date. *Pathogens* 2013; **2**: 1-12 [PMID: 25436878 DOI: 10.3390/pathogens2010001]

70 **Fry AM**, Lu X, Chittaganpitch M, Peret T, Fischer J, Dowell SF, Anderson LJ, Erdman D, Olsen SJ. Human bocavirus: a novel parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand. *J Infect Dis* 2007; **195**: 1038-1045 [PMID: 17330795 DOI: 10.1086/512163]

71 **Dina J**, Vabret A, Gouarin S, Petitjean J, Lecoq J, Brouard J, Arion A, Lafay-Delaire F, Freymuth F. Detection of human bocavirus in hospitalised children. *J Paediatr Child Health* 2009; **45**: 149-153 [PMID: 19210599 DOI: 10.1111/j.1440-1754.2008.01442.x]

72 **Yu JM**, Li DD, Xu ZQ, Cheng WX, Zhang Q, Li HY, Cui SX, Miao-Jin SH, Fang ZY, Duan ZJ. Human bocavirus infection in children hospitalized with acute gastroenteritis in China. *J Clin Virol* 2008; **42**: 280-285 [PMID: 18499516 DOI: 10.1016/j.jcv.2008.03.032]

73 **Campe H**, Hartberger C, Sing A. Role of Human Bocavirus infections in outbreaks of gastroenteritis. *J Clin Virol* 2008; **43**: 340-342 [PMID: 18835213 DOI: 10.1016/j.jcv.2008.07.014]

74 **Proenca-Modena JL**, Martinez M, Amarilla AA, Espínola EE, Galeano ME, Fariña N, Russomando G, Aquino VH, Parra GI, Arruda E. Viral load of human bocavirus-1 in stools from children with viral diarrhoea in Paraguay. *Epidemiol Infect* 2013; **141**: 2576-2580 [PMID: 23425775 DOI: 10.1017/S095026881300023X]

75 **Neske F**, Blessing K, Tollmann F, Schubert J, Rethwilm A, Kreth HW, Weissbrich B. Real-time PCR for diagnosis of human bocavirus infections and phylogenetic analysis. *J Clin Microbiol* 2007; **45**: 2116-2122 [PMID: 17475762 DOI: 10.1128/JCM.00027-07]

76 **Alam MM**, Khurshid A, Shaukat S, Sharif S, Suleman RM, Angez M, Nisar N, Aamir UB, Naeem M, Zaidi SS. 'Human bocavirus in Pakistani children with gastroenteritis'. *J Med Virol* 2015; **87**: 656-663 [PMID: 25611467 DOI: 10.1002/jmv.24090]

77 **Khamrin P**, Malasao R, Chaimongkol N, Ukarapol N, Kongsricharoern T, Okitsu S, Hayakawa S, Ushijima H, Maneekarn N. Circulating of human bocavirus 1, 2, 3, and 4 in pediatric patients with acute gastroenteritis in Thailand. *Infect Genet Evol* 2012; **12**: 565-569 [PMID: 22333841 DOI: 10.1016/j.meegid.2012.01.025]

78 **Santos N**, Peret TC, Humphrey CD, Albuquerque MC, Silva RC, Benati FJ, Lu X, Erdman DD. Human bocavirus species 2 and 3 in Brazil. *J Clin Virol* 2010; **48**: 127-130 [PMID: 20382557 DOI: 10.1016/j.jcv.2010.03.014]

79 **Song JR**, Jin Y, Xie ZP, Gao HC, Xiao NG, Chen WX, Xu ZQ, Yan KL, Zhao Y, Hou YD, Duan ZJ. Novel human bocavirus in children with acute respiratory tract infection. *Emerg Infect Dis* 2010; **16**: 324-327 [PMID: 20113572 DOI: 10.3201/eid1602.090553]

80 **Völz S**, Schildgen O, Klinkenberg D, Ditt V, Müller A, Tillmann RL, Kupfer B, Bode U, Lentze MJ, Simon A. Prospective study of Human Bocavirus (HBoV) infection in a pediatric university hospital in Germany 2005/2006. *J Clin Virol* 2007; **40**: 229-235 [PMID: 17851126 DOI: 10.1016/j.jcv.2007.07.017]

81 **Regamey N**, Frey U, Deffernez C, Latzin P, Kaiser L. Isolation of human bocavirus from Swiss infants with respiratory infections. *Pediatr Infect Dis J* 2007; **26**: 177-179 [PMID: 17259883 DOI: 10.1097/01.inf.0000250623.43107.bc]

82 **Chhabra P**, Payne DC, Szilagyi PG, Edwards KM, Staat MA, Shirley SH, Wikswo M, Nix WA, Lu X, Parashar UD, Vinjé J. Etiology of viral gastroenteritis in children & lt; 5 years of age in the United States, 2008-2009. *J Infect Dis* 2013; **208**: 790-800 [PMID: 23757337 DOI: 10.1093/infdis/jit254]

83 **Guido M**, Quattrocchi M, Campa A, Zizza A, Grima P, Romano A, De Donno A. Human metapneumovirus and human bocavirus associated with respiratory infection in Apulian population. *Virology* 2011; **417**: 64-70 [PMID: 21636105 DOI: 10.1016/j.virol.2011.04.016]

84 **Jiang W**, Yin F, Zhou W, Yan Y, Ji W. Clinical significance of different virus load of human bocavirus in patients with lower respiratory tract infection. *Sci Rep* 2016; **6**: 20246 [PMID: 26832453 DOI: 10.1038/srep20246]

85 **Ghietto LM**, Majul D, Ferreyra Soaje P, Baumeister E, Avaro M, Insfrán C, Mosca L, Cámara A, Moreno LB, Adamo MP. Comorbidity and high viral load linked to clinical presentation of respiratory human bocavirus infection. *Arch Virol* 2015; **160**: 117-127 [PMID: 25269520 DOI: 10.1007/s00705-014-2238-5]

86 **Blessing K**, Neske F, Herre U, Kreth HW, Weissbrich B. Prolonged detection of human bocavirus DNA in nasopharyngeal aspirates of children with respiratory tract disease. *Pediatr Infect Dis J* 2009; **28**: 1018-1019 [PMID: 19730155 DOI: 10.1097/INF.0b013e3181a854ae]

87 **Martin ET**, Fairchok MP, Kuypers J, Magaret A, Zerr DM, Wald A, Englund JA. Frequent and prolonged shedding of bocavirus in young children attending daycare. *J Infect Dis* 2010; **201**: 1625-1632 [PMID: 20415535 DOI: 10.1086/652405]

88 **Peltola V**, Söderlund-Venermo M, Jartti T. Human bocavirus infections. *Pediatr Infect Dis J* 2013; **32**: 178-179 [PMID: 23328822 DOI: 10.1097/INF.0b013e31827fef67]

89 **Manning A**, Willey SJ, Bell JE, Simmonds P. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. *J Infect Dis* 2007; **195**: 1345-1352 [PMID: 17397006 DOI: 10.1086/513280]

90 **Gerna G**, Piralla A, Campanini G, Marchi A, Stronati M, Rovida F. The human bocavirus role in acute respiratory tract infections of pediatric patients as defined by viral load quantification. *New Microbiol* 2007; **30**: 383-392 [PMID: 18080673]

91 **Arnott A**, Vong S, Rith S, Naughtin M, Ly S, Guillard B, Deubel V, Buchy P. Human bocavirus amongst an all-ages population hospitalised with acute lower respiratory infections in Cambodia. *Influenza Other Respir Viruses* 2013; **7**: 201-210 [PMID: 22531100 DOI: 10.1111/j.1750-2659.2012.00369.x]

92 **Do AH**, van Doorn HR, Nghiem MN, Bryant JE, Hoang TH, Do QH, Van TL, Tran TT, Wills B, Nguyen VC, Vo MH, Vo CK, Nguyen MD, Farrar J, Tran TH, de Jong MD. Viral etiologies of acute respiratory infections among hospitalized Vietnamese children in Ho Chi Minh City, 2004-2008. *PLoS One* 2011; **6**: e18176 [PMID: 21455313 DOI: 10.1371/journal.pone.0018176]

93 **Deng Y**, Gu X, Zhao X, Luo J, Luo Z, Wang L, Fu Z, Yang X, Liu E. High viral load of human bocavirus correlates with duration of wheezing in children with severe lower respiratory tract infection. *PLoS One* 2012; **7**: e34353 [PMID: 22479609 DOI: 10.1371/journal.pone.0034353]

94 **Christensen A**, Nordbø SA, Krokstad S, Rognlien AG, Døllner H. Human bocavirus in children: mono-detection, high viral load and viraemia are associated with respiratory tract infection. *J Clin Virol* 2010; **49**: 158-162 [PMID: 20833582 DOI: 10.1016/j.jcv.2010.07.016]

95 **Guidotti LG**, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. *Annu Rev Immunol* 2001; **19**: 65-91 [PMID: 11244031 DOI: 10.1146/annurev.immunol.19.1.65]

96 **Chung JY**, Han TH, Kim JS, Kim SW, Park CG, Hwang ES. Th1 and Th2 cytokine levels in nasopharyngeal aspirates from children with human bocavirus bronchiolitis. *J Clin Virol* 2008; **43**: 223-225 [PMID: 18650126 DOI: 10.1016/j.jcv.2008.06.008]

97 **Lindner J**, Zehentmeier S, Franssila R, Barabas S, Schroeder J, Deml L, Modrow S. CD4+ T helper cell responses against human bocavirus viral protein 2 viruslike particles in healthy adults. *J Infect Dis* 2008; **198**: 1677-1684 [PMID: 18831690 DOI: 10.1086/592985]

98 **Kumar A**, Filippone C, Lahtinen A, Hedman L, Söderlund-Venermo M, Hedman K, Franssila R. Comparison of Th-cell immunity against human bocavirus and parvovirus B19: proliferation and cytokine responses are similar in magnitude but more closely interrelated with human bocavirus. *Scand J Immunol* 2011; **73**: 135-140 [PMID: 21198754 DOI: 10.1111/j.1365-3083.2010.02483.x]

99 **Kantola K**, Hedman L, Arthur J, Alibeto A, Delwart E, Jartti T, Ruuskanen O, Hedman K, Söderlund-Venermo M. Seroepidemiology of human bocaviruses 1-4. *J Infect Dis* 2011; **204**: 1403-1412 [PMID: 21921203 DOI: 10.1093/infdis/jir525]

100 **Hustedt JW**, Christie C, Hustedt MM, Esposito D, Vazquez M. Seroepidemiology of human bocavirus infection in Jamaica. *PLoS One* 2012; **7**: e38206 [PMID: 22666484 DOI: 10.1371/journal.pone.0038206]

101 **Guido M**, Zizza A, Bredl S, Lindner J, De Donno A, Quattrocchi M, Grima P, Modrow S. Seroepidemiology of human bocavirus in Apulia, Italy. *Clin Microbiol Infect* 2012; **18**: E74-E76 [PMID: 22309610 DOI: 10.1111/j.1469-0691.2011.03756.x]

102 **Hao Y**, Gao J, Zhang X, Liu N, Li J, Zheng L, Duan Z. Seroepidemiology of human bocaviruses 1 and 2 in China. *PLoS One* 2015; **10**: e0122751 [PMID: 25923974 DOI: 10.1371/journal.pone.0122751]

103 **Endo R**, Ishiguro N, Kikuta H, Teramoto S, Shirkoohi R, Ma X, Ebihara T, Ishiko H, Ariga T. Seroepidemiology of human bocavirus in Hokkaido prefecture, Japan. *J Clin Microbiol* 2007; **45**: 3218-3223 [PMID: 17699639 DOI: 10.1128/JCM.02140-06]

104 **Jin Y**, Cheng WX, Xu ZQ, Liu N, Yu JM, Li HY, Jin M, Li DD, Zhang Q, Duan ZJ. High prevalence of human bocavirus 2 and its role in childhood acute gastroenteritis in China. *J Clin Virol* 2011; **52**: 251-253 [PMID: 21907613 DOI: 10.1016/j.jcv.2011.07.012]

105 **Manning A**, Russell V, Eastick K, Leadbetter GH, Hallam N, Templeton K, Simmonds P. Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses. *J Infect Dis* 2006; **194**: 1283-1290 [PMID: 17041855 DOI: 10.1086/508219]

106 **Jacques J**, Moret H, Renois F, Lévêque N, Motte J, Andréoletti L. Human Bocavirus quantitative DNA detection in French children hospitalized for acute bronchiolitis. *J Clin Virol* 2008; **43**: 142-147 [PMID: 18644746 DOI: 10.1016/j.jcv.2008.05.010]

107 **Arnold JC**, Singh KK, Spector SA, Sawyer MH. Human bocavirus: prevalence and clinical spectrum at a children's hospital. *Clin Infect Dis* 2006; **43**: 283-288 [PMID: 16804840 DOI: 10.1086/505399]

108 **Maggi F**, Andreoli E, Pifferi M, Meschi S, Rocchi J, Bendinelli M. Human bocavirus in Italian patients with respiratory diseases. *J Clin Virol* 2007; **38**: 321-325 [PMID: 17336143 DOI: 10.1016/j.jcv.2007.01.008]

109 **Arden KE**, McErlean P, Nissen MD, Sloots TP, Mackay IM. Frequent detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus during acute respiratory tract infections. *J Med Virol* 2006; **78**: 1232-1240 [PMID: 16847968 DOI: 10.1002/jmv.20689]

110 **Simon A**, Groneck P, Kupfer B, Kaiser R, Plum G, Tillmann RL, Müller A, Schildgen O. Detection of bocavirus DNA in nasopharyngeal aspirates of a child with bronchiolitis. *J Infect* 2007; **54**: e125-e127 [PMID: 16968654 DOI: 10.1016/j.jinf.2006.08.001]

111 **Chieochansin T**, Chutinimitkul S, Payungporn S, Hiranras T, Samransamruajkit R, Theamboolers A, Poovorawan Y. Complete coding sequences and phylogenetic analysis of Human Bocavirus (HBoV). *Virus Res* 2007; **129**: 54-57 [PMID: 17532505 DOI: 10.1016/j.virusres.2007.04.022]

112 **Foulongne V**, Olejnik Y, Perez V, Elaerts S, Rodière M, Segondy M. Human bocavirus in French children. *Emerg Infect Dis* 2006; **12**: 1251-1253 [PMID: 16965707 DOI: 10.3201/eid1208.060213]

113**Terrosi C**, Fabbiani M, Cellesi C, Cusi MG. Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing. *J Clin Virol* 2007; **40**: 43-45 [PMID: 17686654 DOI: 10.1016/j.jcv.2007.06.011]

114 **I P M**, Nelson EA, Cheuk ES, Leung E, Sung R, Chan PK. Pediatric hospitalization of acute respiratory tract infections with Human Bocavirus in Hong Kong. *J Clin Virol* 2008; **42**: 72-74 [PMID: 18296108 DOI: 10.1016/j.jcv.2007.12.016]

115 **Hamano-Hasegawa K**, Morozumi M, Nakayama E, Chiba N, Murayama SY, Takayanagi R, Iwata S, Sunakawa K, Ubukata K. Comprehensive detection of causative pathogens using real-time PCR to diagnose pediatric community-acquired pneumonia. *J Infect Chemother* 2008; **14**: 424-432 [PMID: 19089556 DOI: 10.1007/s10156-008-0648-6]

116 **Schenk T**, Huck B, Forster J, Berner R, Neumann-Haefelin D, Falcone V. Human bocavirus DNA detected by quantitative real-time PCR in two children hospitalized for lower respiratory tract infection. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 147-149 [PMID: 17216422 DOI: 10.1007/s10096-006-0244-6]

117 **Regamey N**, Kaiser L, Roiha HL, Deffernez C, Kuehni CE, Latzin P, Aebi C, Frey U. Viral etiology of acute respiratory infections with cough in infancy: a community-based birth cohort study. *Pediatr Infect Dis J* 2008; **27**: 100-105 [PMID: 18174876 DOI: 10.1097/INF.0b013e31815922c8]

118 **Böhmer A**, Schildgen V, Lüsebrink J, Ziegler S, Tillmann RL, Kleines M, Schildgen O. Novel application for isothermal nucleic acid sequence-based amplification (NASBA). *J Virol Methods* 2009; **158**: 199-201 [PMID: 19428591 DOI: 10.1016/j.jviromet.2009.02.010]

119 **Lassaunière R**, Kresfelder T, Venter M. A novel multiplex real-time RT-PCR assay with FRET hybridization probes for the detection and quantitation of 13 respiratory viruses. *J Virol Methods* 2010; **165**: 254-260 [PMID: 20153377 DOI: 10.1016/j.jviromet.2010.02.005]

120 **Loeffelholz MJ**, Pong DL, Pyles RB, Xiong Y, Miller AL, Bufton KK, Chonmaitree T. Comparison of the FilmArray Respiratory Panel and Prodesse real-time PCR assays for detection of respiratory pathogens. *J Clin Microbiol* 2011; **49**: 4083-4088 [PMID: 21998418 DOI: 10.1128/JCM.05010-11]

121 **Gendrel D**, Guedj R, Pons-Catalano C, Emirian A, Raymond J, Rozenberg F, Lebon P. Human bocavirus in children with acute asthma. *Clin Infect Dis* 2007; **45**: 404-405 [PMID: 17599330 DOI: 10.1086/521125]

122 **Babady NE**, Mead P, Stiles J, Brennan C, Li H, Shuptar S, Stratton CW, Tang YW, Kamboj M. Comparison of the Luminex xTAG RVP Fast assay and the Idaho Technology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital. *J Clin Microbiol* 2012; **50**: 2282-2288 [PMID: 22518855 DOI: 10.1128/JCM.06186-11]

123 **Balada-Llasat JM**, LaRue H, Kamboj K, Rigali L, Smith D, Thomas K, Pancholi P. Detection of yeasts in blood cultures by the Luminex xTAG fungal assay. *J Clin Microbiol* 2012; **50**: 492-494 [PMID: 22170902 DOI: 10.1128/JCM.06375-11]

124 **Prachayangprecha S**, Schapendonk CM, Koopmans MP, Osterhaus AD, Schürch AC, Pas SD, van der Eijk AA, Poovorawan Y, Haagmans BL, Smits SL. Exploring the potential of next-generation sequencing in detection of respiratory viruses. *J Clin Microbiol* 2014; **52**: 3722-3730 [PMID: 25100822 DOI: 10.1128/JCM.01641-14]

125 **Kantola K**, Hedman L, Allander T, Jartti T, Lehtinen P, Ruuskanen O, Hedman K, Söderlund-Venermo M. Serodiagnosis of human bocavirus infection. *Clin Infect Dis* 2008; **46**: 540-546 [PMID: 18199037 DOI: 10.1086/526532]

126 **Söderlund-Venermo M**, Lahtinen A, Jartti T, Hedman L, Kemppainen K, Lehtinen P, Allander T, Ruuskanen O, Hedman K. Clinical assessment and improved diagnosis of bocavirus-induced wheezing in children, Finland. *Emerg Infect Dis* 2009; **15**: 1423-1430 [PMID: 19788810 DOI: 10.3201/eid1509.090204]

127 **Kahn JS**, Kesebir D, Cotmore SF, D'Abramo A, Cosby C, Weibel C, Tattersall P. Seroepidemiology of human bocavirus defined using recombinant virus-like particles. *J Infect Dis* 2008; **198**: 41-50 [PMID: 18491974 DOI: 10.1086/588674]

128 **Lüsebrink J**, Wittleben F, Schildgen V, Schildgen O. Human bocavirus - insights into a newly identified respiratory virus. *Viruses* 2009; **1**: 3-12 [PMID: 21994534 DOI: 10.3390/v1010003]

129 **Hedman L**, Söderlund-Venermo M, Jartti T, Ruuskanen O, Hedman K. Dating of human bocavirus infection with protein-denaturing IgG-avidity assays-Secondary immune activations are ubiquitous in immunocompetent adults. *J Clin Virol* 2010; **48**: 44-48 [PMID: 20227338 DOI: 10.1016/j.jcv.2010.02.003]

130 **Li X**, Kantola K, Hedman L, Arku B, Hedman K, Söderlund-Venermo M. Original antigenic sin with human bocaviruses 1-4. *J Gen Virol* 2015; **96**: 3099-3108 [PMID: 26224569 DOI: 10.1099/jgv.0.000253]

131 **Lin F**, Guan W, Cheng F, Yang N, Pintel D, Qiu J. ELISAs using human bocavirus VP2 virus-like particles for detection of antibodies against HBoV. *J Virol Methods* 2008; **149**: 110-117 [PMID: 18289709 DOI: 10.1016/j.jviromet.2007.12.016]

132 **Zaghloul MZ**. Human bocavirus (HBoV) in children with respiratory tract infection by enzyme linked immunosorbent assay (ELISA) and qualitative polymerase chain reaction (PCR). *Virol J* 2011; **8**: 239 [PMID: 21595869 DOI: 10.1186/1743-422X-8-239]

133 **Cheng W**, Chen J, Xu Z, Yu J, Huang C, Jin M, Li H, Zhang M, Jin Y, Duan ZJ. Phylogenetic and recombination analysis of human bocavirus 2. *BMC Infect Dis* 2011; **11**: 50 [PMID: 21345238 DOI: 10.1186/1471-2334-11-50]

134 **Jartti L**, Langen H, Söderlund-Venermo M, Vuorinen T, Ruuskanen O, Jartti T. New respiratory viruses and the elderly. *Open Respir Med J* 2011; **5**: 61-69 [PMID: 21760867 DOI: 10.2174/1874306401105010061]

135 **Chow BD**, Ou Z, Esper FP. Newly recognized bocaviruses (HBoV, HBoV2) in children and adults with gastrointestinal illness in the United States. *J Clin Virol* 2010; **47**: 143-147 [PMID: 20036617 DOI: 10.1016/j.jcv.2009.11.030]

136 **Deng ZH**, Hao YX, Yao LH, Xie ZP, Gao HC, Xie LY, Zhong LL, Zhang B, Cao YD, Duan ZJ. Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like particles in mice. *Immunology* 2014; **142**: 58-66 [PMID: 24843872 DOI: 10.1111/imm.12202]

**P-Reviewer:** Adamo MP, Sun YN **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Italy

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0



**Figure 1** **Genomic organization of Human Bocaviruses.** Schematic maps of the Human Bocavirus genomes (HBoV1, RefSeq. NC\_007455.1; HBoV2, RefSeq. NC\_012042.1; HBoV3, RefSeq. NC\_012564.1; HBoV4, RefSeq. NC\_012729.2) were obtained using the Illustrator of Biological Sequences software package[55]. The genes encoding the protein NS1 (non-structural protein), NP1 and VP1/VP2 (capsid proteins) and their nucleotide positions are shown.



**Figure 2** **Similarity plot (generated by SimPlot)[56] of Human Bocaviruses genomes.** A: Each curve is a comparison between the HBoV1 genome (reference) and HBoV2-4 sequences. Nucleotide sequences were aligned using Clustal Omega[57] and the plot was rendered by Simplot using a window size of 200 bp and a step size of 20 bp. The horizontal bars above the curves represent the HBoV1 genes arranged as indicated in Figure 1. B: Phylogenetic trees of nucleotide and amino acid sequences of the HBoV genes. Sequences were aligned by Clustal Omega and phylogenetic analysis was carried out using the Neighbor-Joining method implemented in the MEGA5 program[58]. The numbers at the branch nodes indicate the bootstrap values calculated with 1000 replicates.

**Table 1 Prevalence of human bocavirus infection in respiratory infections and co-infections worldwide from 2005 to 2016**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Country | Numberof studies | Numberof subjects | Prevalenceestimates(%) (95% CI) | Numberof studies | Numberof HBoV+ subjects | Co-infectionsestimates(%) (95%CI) |
| ArgentinaAustraliaBelgiumBrazilCambodiaCanadaChinaDenmarkEgyptFinlandFranceGermanyGreeceHong KongHungaryIndiaIranIsraelItalyJapanJordanKenyaKuwaitMalawiMexicoNew ZealandNicaraguaNigeriaNorwayPeruPortugalSenegalShanghaiSingaporeSloveniaSouth AfricaSouth ArabiaSouth KoreaSpainSwedenSwitzerlandTaiwanThailandThe NetherlandsThe PhilippinesTurkeyUnited KingdomUruguayUnited StatesVietnamTotal | 4101144362111116173322221981111111131321116510163358521081213311 | 1536274544527183779282510696022895454158264595203937099460539472173545016312384735951622301922461853191428312486500891288083375941356095627916572983264512843949149231078135492349233761 | 13.5 (11.8-15.3)13.0 (11.7-14.2)11.5 (8.5-14.4)10.8 (9.6-11.9)1.6 (1.2-2.0)4.1 (3.3-4.8)5.0 (4.9-5.2)25.0 (19.4-30.6)56.8 (46.9-66.8)6.3 (5.6-7.0)6.1 (5.5-6.8)10.1 (9.2-10.9)5.8 (4.8-6.8)7.6 (6.7-8.4)29.8 (20.5-39.0)4.0 (2.4-5.5)7.6 (5.0-10.2)4.0 (2.6-5.5)7.4 (6.8-8.0)10.1 (9.3-10.9)18.3 (14.0-22.6)1.8 (0.5-3.2)1.9 (0.9-2.9)6.3 (1.4-11.2)4.9 (1.6-8.3)3.5 (1.1-5.8)33.3 (26.7-40.0)2.4 (0.5-4.4)12.0 (10.5-13.5)25.1 (19.0-31.3)6.5 (4.2-8.9)1.0 (0.0-2.0)24.5 (20.7-28.3)8.0 (5.6-10.4)18.4 (15.9-21.0)10.3 (9.2-11.4)5.3 (3.8-6.8)5.8 (5.2-6.3)9.9 (9.4-10.4)12.1 (10.1-14.2)4.3 (1.9-6.7)5.6 (4.4-6.7)7.1 (6.2-8.0)6.8 (5.9-7.8)1.0 (0.5-1.6)2.3 (1.8-2.8)1.5 (1.3-1.7)4.1 (2.9-5.3)9.8 (9.3-10.3)5.5 (4.6-6.4)6.3 (6.2-6.4) | 4311022351NG5131031121114511NGNG11NG13NGNG2111541093NG4231441142193 | 2081325129358974,08857NG1972823901189528242126513435577NGNG88NG6222NGNG31194016427839437794116NG624097391024490312810,745 | 55.8 (49.0-62.5)64.4 (56.2-72.6)49.0 (35.3-62.7)90.1 (86.7-93.5)53.4 (40.6-66,3)59.8 (50.0-69.6)50.3 (48.8-51.8)47.4 (34.4-60.3)-61.4 (54.6-68.2)31.2 (25.8-36.6)38.7 (33.9-43.6)48.3 (39.3-57.3)18.9 (11.1-26.8)53.6 (35.1-72.0)8.3 (0.0-19.4)33.3 (13.2-53.5)30.8 (13.0-48.5)62.8 (58.6-67.0)61.1 (56.6-65.7)89.5 (81.5-97.4)100.0 (-)--37.5 (4.0-71.0)37.5 (4.0-71.0)-83.3 (53.5-100)72.1 (66.2-78.0)--33.3 (0.0-86.7)54.6 (45.7-63.6)30.0 (15.8-44.2)59.8 (52.3-67.3)56.8 (51.0-62.7)53.8 (38.2-69.5)43.0 (38.4-47.7)72.2 (69.0-75.3)38.8 (29.9-47.7)-33.9 (22.1-45.7)62.5 (47.5-77.5)66.7 (35.9-97.5)71.4 (38.0-100)30.8 (16.3-45.3)32.4 (23.3-41.4)54.5 (39.8-69.3)38.1 (34.9-41.3)45.3 (36.7-53.9)52.4 (51.5-53.4) |

NG: Not given.

**Table 2 Prevalence of Human Bocavirus infection in gastrointestinal infections and co-infections worldwide from 2005 to 2016**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Country | Numberof studies | Numberof subjects | Prevalenceestimates(% )(95%CI) | Numberof studies | Numberof HBoV+ subjects | Co-infectionsestimates(%) (95%CI) |
| AlbaniaAustraliaBangladeshBrazilChileChinaFinlandGermanyHong KongHungaryIranIrelandItalyJapanMexicoNepalNigeriaPakistanParaguay Russia South KoreaSpainTaiwanThailandTunisiaTurkeyUnited KingdomUnited States Total  | 1315116321141221113123114113268 | 142890138246946288052493338160061621155129142476969649834970311640520110848961501245964044498 | 9.2 (4.4-13.9)8.5 (6.7-10.4)63.0 (55.0-71.1)4.8 (4.0-5.7)19.3 (15.7-22.9)6.6 (6.1-7.1)10.3 (9.1-11.5)8.3 (5.3-11.2)6.4 (5.2-7.6)3.3 (0.0-7.7)14.2 (11.4-16.9)7.7 (3.5-11.9)2.8 (1.9-3.7)3.8 (2.0-5.6)1.3 (0.0-3.9)9.4 (3.5-15.2)29.2 (20.1-38.3)10.6 (7.9-13.4)10.6 (7.4-13.8)1.4 (1.1-1.6)3.8 (2.9-4.8)9.2 (6.7-11.7)3.6 (0.1-7.1)3.8 (2.5-5.1)58.3 (48.5-68.2)8.7 (4.2-13.2)5.4 (5.0-5.7)3.6 (2.2-5.0)5.9 (5.7-6.1) | 1NGNG5NG822NGNG11221NGNG11221NG3NGNG1NG36 | 13NGNG119NG38025128NGNG161236161NGNG4737955548NG19NGNG324NG1497 | 23.1 (0.2-46.0)--15.1 (8.7-21.6)-67.4 (62.7-72.1)32.7 (26.9-38.5)28.6 (11.8-45.3)--0.0 (0.0-0.0)100.0 (100.0-100.0)22.2 (8.6-35.8)62.5 (38.8-86.2)100.0 (100.0-100.0)--97.9 (93.7-100.0)40.5 (24.7-56.4)49.5 (39.4-59.5)14.5 (5.2-23.9)52.1 (38.0-66.2)-57.9 (35.7-80.1)--46.0 (40.6-51.4)-46.7 (44.2-49.2) |

NG: Not given.